Dual TCR Editing Improves Engineered T Cell Specificity

Company Columbia University (academic) Event Type Peer-reviewed publication (JCI Insight, previously missed 17 Nov paper) Modality CRISPR-Cas9 endogenous TCR deletion with transgenic TCR Asset TRAC/TRBC1/2 boundary-targeted editing Target Endogenous TCR alpha and beta chains Disease Area Melanoma (MART-1 model); autoimmunity models Summary An online-first peer-reviewed…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *